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An increasing number of genes involved in chromatin structure and epigenetic regulation has been implicated in a variety of develop-
mental disorders, often including intellectual disability. By trio exome sequencing and subsequent mutational screening we now
identified two de novo frameshift mutations and one de novo missense mutation in CTCF in individuals with intellectual disability,
microcephaly, and growth retardation. Furthermore, an individual with a larger deletion including CTCF was identified. CTCF
(CCCTC-binding factor) is one of the most important chromatin organizers in vertebrates and is involved in various chromatin
regulation processes such as higher order of chromatin organization, enhancer function, and maintenance of three-dimensional
chromatin structure. Transcriptome analyses in all three individuals with point mutations revealed deregulation of genes involved in
signal transduction and emphasized the role of CTCF in enhancer-driven expression of genes. Our findings indicate that haploinsuffi-
ciency of CTCF affects genomic interaction of enhancers and their regulated gene promoters that drive developmental processes and
cognition.Chromatin organization that controls compartmentaliza-
tion of distinct functional domains has a fundamental
impact on correct temporal and spatial gene expression
required for proper development and cognition in the
mammalian genome.1,2 An increasing number of genes
involved in chromatin structure and epigenetic regulation
has been implicated in various developmental disorders,
often including intellectual disability (ID).3 Examples are
EHMT1 (MIM 607001), encoding euchromatin histone
methyl transferase 1, in Kleefstra syndrome4 (MIM
610253), and ARID1B (MIM 614556) and other genes
encoding for subunits of the SWI/SNF complex in unspe-
cific ID (MIM 614562) or Coffin-Siris syndrome (MIM
135900).5–7 We now identified de novo mutations in the
key chromatin organizer CTCF (MIM 604167) in individ-
uals with intellectual disability.
We performed trio exome sequencing in an individual
(I1) with mild ID, short stature, microcephaly, cleft palate,
and congenital heart defect (Figure 1 and Table 1). The
SureSelect Human All Exon Kit V3 (50 Mb, ~21,000 genes)
(Agilent Technologies) was used for enrichment, and
sequencing was carried out with 50 bp single reads on a
SOLiD 4 system (Life Technologies). On average, we ob-
tained more than 100 million reads per individual. Read
mapping to the UCSC Genome Browser hg19 reference
genome was performed with SOLiD LifeScope software
v.2.5 and yielded approximately 82 million mappable
reads per individual. The mean target coverage was 72,
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software v.2.5 with high stringency settings and GATK
v.1.48 after local realignment of indels. Only variants called
by LifeScope with high stringency settings and by GATK
were selected. The study was approved by the ethics com-
mittee of the Medical Faculty, University of Erlangen-
Nuremberg, and informed consent was obtained from
parents or guardians of the affected individuals.
For individual I1, a total of 29,523 variants (SNVs and
indels) were annotated. We examined the data for
de novomutations by excluding variants present in dbSNP
135 or our in-house database of 234 exomes, in noncoding
regions or in either of the parents (Tables S1 and S2
available online). We detected two de novo mutations.
One of these is the frameshifting mutation c.375dupT
(p.Val126Cysfs*14) in CTCF (RefSeq accession number
NM_006565.3) (Figure S1). No convincing truncating
mutations or copy-number variants in CTCF were
observed in dbSNP 135, 1000Genomes, the Exome Variant
Server (EVS), our in-house databases comprisingmore than
1,500 exomes (234 from Erlangen and 1,298 from Nijme-
gen), or 820 molecularly karyotyped healthy controls.
CCCTC-binding factor CTCF is an important chromatin
organizer involved in a range of gene regulation processes.
When bound to insulator elements, CTCF can prevent
spreading of inactive heterochromatin into neighboring
regions and shield particular gene promoters from
enhancer function.9 This enhancer blocking by CTCF
might be methylation sensitive.10,11 CTCF is involved inerg, 91054 Erlangen, Germany; 2Department of HumanGenetics, Nijmegen
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Figure 1. Identified Defects in CTCF
(A) Schemes of the genomic and protein structure of CTCF with localization and electropherograms of the mutations. Themutations are
named according to isoform 1 of CTCF (RefSeq NM_006565.3).
(B) Conservation of the missense mutation. The position of the mutation at amino acid 567 is indicated by a blue bar and highly
conserved throughout all indicated species.
(C) Clinical pictures of the affected individuals with unspecific facial gestalt.maintaining three-dimensional chromatin structure,12
imprinting,10 X inactivation,13 and nucleosome posi-
tioning.9,14–17 The crucial role of CTCF in development9
is reflected in early implantation lethality upon complete
CTCF deficiency in mice.18 In another mouse model in
which 70% of genomic Ctcf was depleted in specific neu-
rons, postnatal growth retardation, abnormal behavior,
and brain abnormalities were observed, thus underscoring
the function of CTCF in cognition and other develop-
mental processes.19 Several lines of evidence indicate that
CTCF also plays a role in disease-related phenotypes in
humans. Deregulation of CTCF binding has been impli-
cated in overgrowth and growth retardation disorders
resulting from aberrant methylation of the imprinted
H19/IGF2 locus.20,21 Genomic CTCF binding sites sig-
nificantly overlap with SNPs associated with human
height.22 Also, cohesins that mediate enhancer blocking
by recruiting CTCF binding to insulator sites23 are mutated
in Cornelia-de-Lange syndrome (MIM 122470), a disorder
with severe ID andmultiple congenital anomalies. Somatic
mutations in CTCF, among other chromatin modifiers,The Amwere observed in two cases of acute leukemia.24,25 So far,
germline mutations in CTCF have not been reported.
We next screened CTCF (RefSeq NM_006565.3) in 399
individuals with intellectual disability by unidirectional
direct sequencing (ABI BigDye Terminator Sequencing Kit
v.3; Life Technologies) of all coding exons with exon-
intron boundaries with an automated capillary sequencer
(ABI 3730; Life Technologies). We identified two further
mutations in two boys: a de novo frameshift mutation
c.1186dupA (p.Arg396Lysfs*13) (I2) and a de novo
missense mutation c.1699C>T (p.Arg567Trp) (I3) (Fig-
ure 1). All mutations were excluded in dbSNP 135, 1000
Genomes, EVS, and our in-house databases. I2 had border-
line intelligence but developmental delay, pronounced
learning difficulties, and behavioral problems. Further-
more, microcephaly was noted. I3 had severe ID with
autistic features, microcephaly, and severe feeding diffi-
culties, still requiring tube feeding at the age of 4 years
(Table 1). Shared clinical features in all three individuals
with de novo mutations in CTCF comprised ID of variable
severity (with I3 being most severely affected), headerican Journal of Human Genetics 93, 124–131, July 11, 2013 125
Table 1. Summarized Clinical Findings in the Affected Individuals
Individual 1 Individual 2 Individual 3 Individual 4
Defect in CTCF
(NM_006565.3)
c.375dupT
(p.Val126Cysfs*14)
c.1186dupA
(p.Arg396Lysfs*13)
c.1699C>T
(p.Arg567Trp)
280 kb deletion, eight genes
Gender male male male female
Age at last investigation 9 years, 6 months 9 years 3 years, 11 months 15 years
Birth 34 weeks 40 weeks 39 weeks 40 weeks
Birth weight SGA 2,620 g 2,990 g 2,900 g
Birth length SGA 50 cm 54 cm 49 cm
Birth OFC SGA 33 cm 34 cm ND
Feeding difficulties first years first week tube feeding yes
Muscular hypotonia ND yes yes yes
Weight 20 kg, 2.35 SD 25.6 kg, 0.96 SD 13.4 kg, 1.15 SD 40.5 kg, 1.74 SD
Height 125.5 cm, 3.15 SD 129.5 cm, 0.71 SD 100 cm, 1.9 SD 156 cm, 1.94 SD
OFC 48.2 cm, 3.51 SD 49.5 cm, 2.61 SD 47.5 cm, 2.91 SD 54 cm, 0.84 SD
Developmental delay/
intellectual disability
IQ 64 Dev. delay, IQ 79–86 severe moderate
Age of walking 24 months 18 months 23 months 30 months
Age of first words 4 years >18 months 2 words at 3 years 2 years
Behavioral anomalies no easily overstrained autistic behavior sleeping disturbances, autistic
behavior, temper tantrums
Brain anomalies ultrasound: wide ventricles,
plexus cyst
ND normal MRI CT at 1 year: dilated left
ventricle
Recurrent infections no yes no no
Hypermetropia yes, plus strabism no yes yes, plus strabism
Hearing tested normal appeared normal tested normal tested normal
Urogenital anomalies inguinal hernia cryptorchidism cryptorchidism, phimosis ND
Minor, unspecific facial
dysmorphisms
small mouth, prominent
incisors, small other teeth,
thin upper lip
pointed nose, thin upper lip thin lips high forehead, hypertelorism,
thick eyebrows, long
eyelashes, epicanthic folds,
low-set posteriorly rotated
ears, long philtrum, thin lips
Other anomalies ASD, PDA, mild aortic
coarctation, cleft palate,
prominent finger joints,
single palmar crease, sacral
dimple, camptodactyly V
clinodactyly finger V, single
palmar crease, dental
anomalies
none hypertrichosis, sandal gaps,
broad 1st toe
Normal previous testing 22q11.2-FISH, UPD7, UPD14,
Fragile-X, Affymetrix 6.0
Mapping SNP array
Affymetrix 6.0 Mapping SNP
array, Fragile-X
muscle biopsy, metabolic
screening, 22q11.2-MLPA,
Affymetrix 6.0 Mapping SNP
array, Fragile-X, methylation
test for Angelman syndrome
ND
Abbreviations are as follows: ASD, atrial septum defect; FISH, fluorescence in situ hybridization; MLPA, multiplex ligation-dependent probe amplification; ND, no
data; PDA, persistent ductus arteriosus; SD, standard deviation; SGA, small for gestational age.circumference and/or body height either in the low
normal range or below –2 standard deviations, and feeding
difficulties (Figure 1, Table 1). Mice with reduced levels of
CTCF in neurons19 have overlapping phenotypes with
affected individuals, thus emphasizing its role in physical
and cognitive development. Apart from a mild congenital
heart defect and cleft palate in I1, no gross malformations
or specific dysmorphisms were observed in the individuals
reported here.126 The American Journal of Human Genetics 93, 124–131, July 11, 2To test the consequences of the mutations, CTCFmRNA
expression and protein levels were determined. Expression
analysis on lymphocyte cDNA, reversely transcribed from
RNA extracted with the PAXgene Blood System (Becton
Dickinson), was done by quantitative RT-PCR with the
SYBRgreen mastermix (Thermo Fisher Scientific) on an
ABI 7900HT instrument (Life Technologies). We found
reduced expression of CTCF in both individuals with
frameshift mutations (I1 and I2). Sequencing of the013
cDNA confirmed almost complete absence of the
mutated allele (Figure S3). This observation is consistent
with loss of function or haploinsufficiency, possibly
through nonsense-mediated mRNA decay. A search of
the Decipher database yielded one girl with intellectual
disability (I4) and a de novo deletion of eight genes
including CTCF (Figure S2), again supporting the notion
that haploinsufficiency of CTCF gives rise to the ID pheno-
type. In I3 (harboring the missense mutation) the
mutation was still detectable in cDNA, and CTCF mRNA
expression levels as well as CTCF protein levels were unal-
tered (Figure S3). This missense mutation is located in the
splice donor consensus site of exon 9. RT-PCR did not
reveal an aberrant splice product (data not shown). Two
of three prediction programs indicated a deleterious effect
of this missense variant (Table S3). This variant was absent
in dbSNP 135, 1000 Genomes, EVS, and in-house exomes.
Molecular modeling indicated that the c.1699C>T
(p.Arg567Trp) exchange does not cause steric problems
in the CTCF structure, suggesting that the mutation has
no significant effect on protein stability. Modeling DNA-
bound CTCF indicated that replacement of an arginine
by a tryptophane at position 567 would result in weaker
interactions with the DNA backbone compared to the
wild-type and in novel nonpolar interactions formed
with the bases of the DNA (Figure S4). Therefore, the
c.1699C>T (p.Arg567Trp) mutation might affect both
DNA binding affinity and specificity. This is compatible
with a disease model of either functional haploinsuffi-
ciency or a dominant-negative effect. We note that this
individual harbors a second de novo variant in the
same exon that we showed to be on the same allele
(c.1650C>T [p.(¼)]) (Figure S5). Because it is not located
in the splice site and does not result in an amino acid
change, a pathogenic relevance is not obvious. However,
a contributory effect additionally to themissensemutation
cannot be excluded.
Because of the known role of CTCF in transcriptional
regulation and chromatin organization, we performed
whole-transcriptome (mRNA) sequencing on lymphocyte
RNA from I1, I2, I3, and eight healthy control individuals.
Total RNAwas amplified with the Ovation RNA-Seq system
(NuGEN). Amplified ds-cDNA was then used for library
preparation and sequenced on a SOLiD4 system (Life Tech-
nologies). On average, 30 of 81million reads per individual
(38%) were mapped to the UCSC Genome Browser hg19
reference genome with Bowtie26 v.0.12.7 with a SNP frac-
tion of 0.001. Mapped reads were assigned to transcripts
of the March 9, 2012, version of the Illumina iGenomes
transcriptome with HTSeq v.0.5.3p9 with default settings,
resulting in an average of 7.5 million assigned reads per
individual. Differential expression between affected and
control individuals was determined with the count-based
DESeq R package.27 Gene expression differed between
affected and control individuals when considering genes
of moderate to high expression (reads per kilobase per
millionmapped reads [RPKM]> 10; applies to 5,088 genes)The Am(Figures 2 and S6). The gene expression patterns of the two
individuals with frameshift mutations (I1 and I2) were
more similar to each other than to I3 with the missense
mutation (Figure 2). This divergent expression profile
might provide a possible explanation for the more severe
clinical phenotype associated with the missense mutation.
Nonetheless, the overlap of down- and upregulated genes
in I3 compared to I1 and I2 was significant (p < 10197
and p < 1031, respectively, chi-square test) (Figure S7),
supporting a shared pathogenic mechanism. Twelve of
the deregulated genes were validated by quantitative RT-
PCR (Figure S8). Six were randomly selected, and five
were neuronal genes with a deregulated gene expression
pattern that was consistent with that in brain tissues of
neuron-specific knockout mice.19 In addition, because pro-
tocadherin (Pcdh) genes were shown to be deregulated in
these mice,19 we also validated PCDH9 (MIM 603581),
the only PCDH gene expressed at a reasonable level in lym-
phocytes (Figure S8).
Evaluating our set of 698 downregulated genes with
regards to Gene Ontology28 terms, we found enrichment
primarily for genes involved in cellular response to extra-
cellular stimuli (Figures S9 and S10 and Table S4), processes
that are implicated in developmental and cognitive disor-
ders.29 These Gene Ontology terms are also consistent
with findings in neuron-specific knockoutmice.19 Interest-
ingly, the set of 118 upregulated genes was much smaller,
which was also in line with the gene expression pattern
in neuron-specific knockout mice.19 These upregulated
genes were dominated by ribosomal genes, suggesting up-
regulation of mRNA translation as a possible compensa-
tory mechanism.
To investigate whether heterozygous CTCF mutations
might be associated with disorganized chromatin
domains, we performed chromatin immunoprecipitation
followed by deep sequencing (ChIP-seq). After isolating
lymphocytes from Heparin blood of a human control indi-
vidual with a swelling buffer, cells were cross-linked and
harvested as described previously.30 Chromatin was soni-
cated with a Bioruptor sonicator (Diagenode), and ChIP
was performed with a CTCF antibody (Millipore; 07-729).
After barcording with NEXTflex adaptors, three samples
were sequenced in one lane on a HiSeq 2000 (Illumina).
Out of 46 million 50 bp single-end reads passing the
Illumina chastity filter, 44 million (96%) were mapped to
the human GRCh37 genome (UCSC Genome Browser
hg19; assembly February 2009) via BWA.31 Prior to peak-
calling and visualization, all duplicate reads and reads
mapping to repeat regions were removed. We found
27,072 CTCF binding sites, of which 14,729 contained
CTCFmotifs. CTCFmotifs were detected in ChIP-seq peaks
with the FIMO program32 of the MEME suite v.4.8.133 with
the CTCF position weight matrix from the JASPAR data-
base,34 with genome-wide UCSC Genome Browser hg19
nucleotide frequencies as background and a p value
threshold of 104 (multiple testing corrected p value <
0.06). The peak-per-gene density was clearly higher inerican Journal of Human Genetics 93, 124–131, July 11, 2013 127
Figure 2. Gene Expression and Promoter-Enhancer Interaction in CTCF-Deficient Individuals
(A) Gene expression similarity between individuals for the 816 differentially expressed genes with corrected p value < 0.05 (698 down,
118 up). Both individuals and genes are clustered by the correlation distance. Blue, downregulated; red, upregulated.
(B) Variation inmean peak-per-gene density for CTCFmotif-containing lymphocyte ChIP-seq peaks of different gene categories. Colored
lines show mean density in consecutive nonoverlapping 200 kb windows within a 2 Mb region around gene transcription start
sites. CTCF peak-to-gene ratio is enriched near downregulated genes relative to similarly expressed or upregulated genes (p < 104
and p < 1020, respectively, for the region between 500 kb and þ500 kb around transcription start site, Wilcoxon test). Peaks were
called via MACS software with default settings, with the ENCODE UW Gm12878 lymphoblastoid cell line ChIP-seq input track used
as background control. The BEDTools suite40 was used for overlap determination and the R statistical software package41 for mean
density calculations and statistics. Genes less than 1 Mb from chromosome ends were excluded. Legend: All, all genes expressed at
RPKM > 10 (4,724 genes); Similar, set of nondifferentially expressed RPKM > 10 genes (1,841 genes); Down/Up, RPKM > 10 genes
that are down- or upregulated in affected individuals (671/108 genes).
(C) Enrichment of promoters that interact exclusively with enhancers and depletion of promoter-promoter interactions in downregu-
lated genes (numbers above bars indicate absolute gene counts; chi-square test, *p < 103, ***p < 109). The control set of nondifferen-
tially expressed genes consists of the RPKM > 10 genes with an affected-control fold change of less than 1.2 and a p value of more than
0.3 (1,986 genes). Legend: All, all genes expressed at RPKM > 10; Similar, nondifferentially expressed subset; Down/Up, subsets that are
down- or upregulated in affected individuals.the genomic regions containing downregulated genes
than in those with upregulated or similarly expressed
genes (Figure 2 and Table S5) (p < 104 and p < 1020,
respectively, in 1 Mb windows around gene promoters,
Wilcoxon test). Similarly, the peaks near downregulated
genes had higher peak scores than those near similarly ex-
pressed genes (p < 0.001, Wilcoxon test) (Figure S11).
Thus, in individuals with CTCF haploinsufficiency, the
higher number of CTCF binding sites per gene for downre-
gulated relative to upregulated or unaltered genes suggests
that activation of these genes is regulated by CTCF. A
recent CTCF-associated chromatin interactome map in128 The American Journal of Human Genetics 93, 124–131, July 11, 2murine embryonic stem cells has demonstrated a role of
CTCF in connecting distinct domains for gene expression
regulation.17 Additionally, CTCF-mediated chromatin
interaction has recently been shown to poise an inducible
gene for increased transcription in response to extracel-
lular stimulation.35 We therefore hypothesized that CTCF
mutations may result in destabilized chromatin interac-
tions required for gene expression.
To test this hypothesis, we first investigated whether
differentially regulated genes are associated with CTCF
chromatin loops. Because data on chromatin interaction
analysis with paired-end-tag sequencing (ChIA-PET) of013
CTCF was not available from lymphocytes, we obtained
K562 (a chronic myelogenous leukemia cell line) RNA
polymerase II and CTCF ChIA-PET interactions from
the ENCODE36 data collection center at the UCSC
Genome Browser database.37 K562 CTCF interactions
were filtered for those with CTCF motif-containing
ChIP-seq peaks from Heparin blood lymphocytes at
both anchors (7,453 of 25,721 interactions). We found
that downregulated but not upregulated genes are located
within CTCF loops more frequently than expected (p <
103 and p ¼ 0.25, respectively, hypergeometric test)
and that similarly expressed genes are underrepresented
(p < 105).
We used ChIA-PET interaction data of RNA polymerase
II from K562 cells38 to investigate the chromatin interac-
tion pattern of affected gene promoters. We found that
the downregulated genes in the herewith reported indi-
viduals were enriched for promoters that exclusively
interact with enhancers and depleted for genes whose
promoters cluster with other promoters (Figures 2 and
S12). Furthermore, EP300 ChIP-seq peaks, which are
indicative of active enhancers,39 were clearly enriched in
the vicinity of downregulated genes relative to similarly
expressed and upregulated genes in both the ENCODE
lymphoblastoid and K562 cell lines (Figure S13) (p <
106 to p < 103 for all comparisons, with a 1 Mb
window around promoter, Wilcoxon test). These data
indicate that CTCF deficiency predominantly affects
expression of enhancer-regulated genes. CTCF-associated
loops possibly stabilize promoter-enhancer interac-
tions,17 thereby increasing their efficiency and the levels
of gene expression. These data are consistent with a
model in which CTCF leads to stabilization of distinct
transcription domains.
Taken together, de novo mutations in CTCF in humans
cause variable impairment of cognition and growth.
Haploinsufficiency is probably the disease mechanism of
the phenotypes. Our data suggest that CTCF is required
for enhancer-driven gene activation and genomic interac-
tion of enhancers and their regulated gene promoters in
development.Supplemental Data
Supplemental Data include 13 figures and 8 tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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